GGrantIndex
Sort

10,766 grants matching checkpoint inhibitor

Project 1 Targeting the PI3K Pathway to Overcome Resistance to Immunotherapy in Melanomas with Loss of PTEN

$531,105
Michael Davies · University Of Tx Md Anderson Can Ctr · P50 · FY2020 · CA

Systems analysis of cell-cell communication networks and immune activity in the melanoma tumor microenvironment

$530,976
Kathryn Miller-Jensen · Yale University · U01 · FY2024 · CA

Integrated Discovery Pipeline for Tumor Neoantigens

$530,736
Beatriz M. Carreno · University Of Pennsylvania · R01 · FY2019 · CA

Targeting the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer with a Neoadjuvant Platform Clinical Trial

$530,360
Elizabeth Marion Jaffee · Johns Hopkins University · R01 · FY2024 · CA

Translation of commensal bacteria mechanism for immunotherapy

$530,298
Howard C Hang · Rockefeller University · R01 · FY2020 · CA

Studies of Materials with Physiological Properties

$530,266
Harvard University · R01 · FY2003 · GM

Dissecting the immunomodulatory effects of NK cells on immune responses to cancer

$530,015
Kevin C Barry · Fred Hutchinson Cancer Center · R01 · FY2024 · CA

Project 1-Combination Immunotherapy with Radioligned Therapy for Metastatic Prostate Cancer

$529,989
Lawrence Fong · University Of California, San Francisco · P50 · FY2025 · CA

Developing translationally-relevant genetically engineered mouse models of lung adenocarcinoma for investigations in cancer immunology

$529,878
Nikhil Joshi · Yale University · R01 · FY2024 · CA

Cell-Selective CpG-STAT3 Inhibitors for Radioimmunotherapy of Malignant Glioma

$529,603
Marcin Kortylewski · Beckman Research Institute/City Of Hope · R01 · FY2018 · CA

STING-Activating Polymeric Nanovaccines for T Cell Therapy of Melanoma

$529,462
Jinming Gao · Ut Southwestern Medical Center · U01 · FY2020 · CA

Use of a Nano-Enabled Platform for Pancreatic Cancer Immunotherapy

$529,313
Andre Elias Nel · University Of California Los Angeles · R01 · FY2022 · CA

Fractionated photoimmunotherapy to harness low-dose immunostimulation in ovarian cancer

$529,280
Bryan Quilty Spring · Northeastern University · U01 · FY2023 · CA

Dual-specificity phosphatase action in muscle disease

$529,254
Anton M Bennett · Yale University · R01 · FY2023 · AR

Nanovaccine platforms to combat pancreatic cancer

$529,150
Balaji Narasimhan · Iowa State University · U01 · FY2019 · CA

Immunogenomic predictors of outcomes in patients with locally advanced cervical cancer treated with immunotherapy and chemoradiation

$529,039
Dmitriy Zamarin · Icahn School Of Medicine At Mount Sinai · R01 · FY2025 · CA

Interrogating Type I Interferon signaling in breast cancer brain metastasis

$529,002
Qing Chen · Wistar Institute · R01 · FY2024 · CA

Defining the Pathogenesis and Prognosis of Human Acute Interstitial Nephritis

$528,788
Lloyd G Cantley · Yale University · R01 · FY2022 · DK

Glutaredoxin, Glutathione Metabolism and Lung Cancer

$528,642
Yvonne M.w. Janssen-Heininger · University Of Vermont & St Agric College · R01 · FY2025 · CA

Defining the Pathogenesis and Prognosis of Human Acute Interstitial Nephritis

$528,629
Lloyd G Cantley · Yale University · R01 · FY2021 · DK

Targeting PD-L1 interactome signaling to enhance immunotherapy efficacy in head and neck squamous cell cancer

$528,427
Antonio Jimeno · University Of Colorado Denver · R01 · FY2025 · CA

Plasmonic nanoparticle-mediated immunotherapy to treat metastatic cancer

$528,416
Tuan Vo-Dinh · Duke University · R01 · FY2022 · EB

CPTR - Mass Spectrometry Unit

$528,384
Lisa Jenkins · Division Of Basic Sciences - Nci · ZIC · FY2020 · CA

TCR-antigen foundation model to empower TCR-based diagnostics and therapeutics

$528,157
Tao Wang · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · AI

Targeting PIM-2 Kinase for Improving Cancer Immunotherapy

$528,033
Xue-Zhong Yu · Medical College Of Wisconsin · R01 · FY2023 · CA